FINAL EXAM NATIONAL BOARD OF EXAMINATIONS
DECEMBER 2017

POSSESSION/USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE EXAMINATION HALL.
HEMATOLOGY
PAPER-III
HEM/D/17/48/III
Time 3 hours
Max. Marks :100
• Attempt all questions in order.
• Each question carries 10 marks.
• Read the question carefully and answer to the point neatly and legibly.
• Do not leave any blank pages between two answers.
• Indicate the question number correctly for the answer in the margin space
• Answer all the parts of a single question together.
• Start the question to a question on a fresh page or leave adequate space between two answers.
• Draw table/diagrams/flowcharts wherever appropriate.
Write short notes on:
1. WHO classification of acute leukemia 2016:
What are the changes in ALL?
What are germ line malignancy?
How this classification is better than 2008
classification?

2. Thalassemia:
Monitoring iron overload
Long term endocrinological complications and their
management
Hematopietic stem cell transplant in thalassemia

3. Allogenic hematopoietic stem cell transplantation
Haploidentical HSCT
Role of killer immunoglobulin like receptors.
Its role in therapy of AML.

4. Classification of vWD
Diagnosis of subtypes
Management of vWD

5. Hemophilia:
Diagnosis of coagulations factor defects.
Newer FVIII replacement options.
How do you decide which factors to use?
Management of hemophiliac joint arthropathy

6. Hodgkin's lymphoma:
Role of PET-CT.
Risk adapted approach in the management of
Hodgkin's lymphoma.
Place of hematopoietic stem cell transplantation in the
management algorithm.

FINAL EXAM NATIONAL BOARD OF EXAMINATIONS
DECEMBER 2017

POSSESSION/USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE EXAMINATION HALL.
7. Lab approach to diagnose inherited thrombophilia.
ISTH guidelines for management of anti-phospholipic
syndrome
Newer anti coagulants

8. Causes of acquired platelet dyfunctions.
Newer anti platelet agents
Lab monitoring of anti platelet agents.

9. CML:
How will you manage CML patient?
Imatinib resistance.
International standardization of BCR-ABL.

10. Approach to treatment with newer agents in multiple
myeloma
Therapeutic strategies in sickle cell anemia
Optimizing therapy in follicular lymphoma